Brookline Capital Markets Starts Cardiol Therapeutics (CRDL) at Buy, PT $6

Brookline Capital Markets analyst Tyler Bussian initiates coverage on Cardiol Therapeutics (NASDAQ: CRDL) with a Buy rating and a price target of $6.00.

The analyst comments "We initiate coverage of Cardiol Therapeutics Inc. (CRDL) with a BUY rating and a DCF-derived target price of $6 per share. CRDL’s lead asset, CardiolRx, is an oral anti-inflammatory being advanced in recurrent pericarditis and acute myocarditis. The compound is designed to address immune- mediated cardiac inflammation, with pivotal development in recurrent pericarditis (MAVERIC - NCT06708299) and promising Phase 2 data in acute myocarditis (ARCHER - NCT05180240). Our Target Price reflects the present value of future cash flows from CardiolRx in recurrent pericarditis ($3/share) and acute myocarditis ($1/share), as well as a 50% international multiplier ($2/share)."

For an analyst ratings summary and ratings history on Cardiol Therapeutics click here. For more ratings news on Cardiol Therapeutics click here.

Shares of Cardiol Therapeutics closed at $1.08 yesterday.

You May Also Be Interested In

• Churchill Downs (CHDN) PT Lowered to $131 at Stifel, Stays on Stifel Select List
• Bayfirst Financial Corp (BAFN) Tops Q3 EPS by 4c
• Seaport Global Securities Starts Anthropic (ANT), Defers Offering Rating